Latest Breaking News On - Abelson tyrosine kinase - Page 5 : comparemela.com

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

- Pre-NDA Meeting to discuss requirements for a 505 NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - - Bioequivalence to 400 mg and 600 mg imatinib mesylate.

United statesMilton wernerAlex loboMiltonh wernerCompany contactDrug administrationStern investor relations incInhibikase therapeutics incExchange commissionInhibikase or companyAbelson tyrosine kinasesNew drug applicationChief executive officerAbelson tyrosine kinaseOrphan drug designationAbleson tyrosine

Inhibikase Therapeutics (IKT) Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics (IKT) Granted Pre-NDA Meeting with the FDA for IkT-001Pro
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMilton wernerDrug administrationInhibikase or companyInhibikase therapeutics incInhibikase therapeuticsAbelson tyrosine kinasesNew drug applicationChief executive officerAbelson tyrosine kinaseOrphan drug designation

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMiltonh wernerRisvodetinib ikAlex loboInhibikase or companySternir incInhibikase therapeutics incEuropean unionExchange commissionMovement disorder congressCompany contactHighlights recent periodAbelson tyrosine kinasesChief executive officerMultiple systemUpcoming milestones

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period

BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course

United statesAlex loboRisvodetinib ikMiltonh wernerCompany contactExchange commissionSternir incInhibikase therapeutics incEuropean unionInhibikase or companyMovement disorder congressAbelson tyrosine kinasesChief executive officerMultiple systemUpcoming milestonesOrphan drug designation

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage phar.

United statesMiltonh wernerRisvodetinib ikAlex loboInhibikase therapeutics incCompany contactMovement disorder congressInhibikase or companyEuropean unionSternir incExchange commissionAbelson tyrosine kinasesChief executive officerMultiple systemUpcoming milestonesOrphan drug designation